BridgeBio Pharma (BBIO) Other Accumulated Expenses (2018 - 2026)

BridgeBio Pharma (BBIO) has 9 years of Other Accumulated Expenses data on file, last reported at $135.5 million in Q1 2026.

• For the quarter ending Q1 2026, Other Accumulated Expenses rose 991.23% year-over-year to $135.5 million; the trailing twelve-month figure through Mar 2026 stood at $135.5 million (up 991.23% YoY), and the FY2025 full-year result was $120.2 million, up 263.53% from the prior year.
• Other Accumulated Expenses climbed to $135.5 million in Q1 2026, from $120.2 million in the prior quarter.
• In the past five years, Other Accumulated Expenses ranged from a high of $135.5 million in Q1 2026 to a low of $4.7 million in Q4 2023.
• A 5-year average of $38.2 million and a median of $23.0 million in 2022 frame the typical range for Other Accumulated Expenses.
• Across the five-year window, Other Accumulated Expenses slumped 82.86% in 2022 and jumped 991.23% in 2026, its largest moves.
• Tracing BBIO's Other Accumulated Expenses over 5 years: stood at $5.2 million in 2022, then slipped by 10.27% to $4.7 million in 2023, then soared by 610.14% to $33.1 million in 2024, then soared by 263.53% to $120.2 million in 2025, then climbed by 12.72% to $135.5 million in 2026.
• Business Quant data shows BBIO's Other Accumulated Expenses at $135.5 million in Q1 2026, $120.2 million in Q4 2025, and $92.7 million in Q3 2025.